Barclays
ZBIO

Barclays’s Zenas BioPharma ZBIO Stock Holding History

Barclays’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$579K Sell
29,610
-4,767
-14% -$107K ﹤0.01% 3100
2025
Q4 		$1.25M Buy
34,377
+11,501
+50% +$378K ﹤0.01% 3286
2025
Q3 		$508K Sell
22,876
-4,937
-18% -$80.4K ﹤0.01% 3802
2025
Q2 		$270K Buy
27,813
+11,653
+72% +$113K ﹤0.01% 4101
2025
Q1 		$128K Sell
16,160
-7,779
-32% -$60.9K ﹤0.01% 4304
2024
Q4 		$196K Buy
23,939
+8,439
+54% +$132K ﹤0.01% 4324
2024
Q3 		$262K Buy
+15,500
New +$279K ﹤0.01% 4155

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Barclays's ZBIO Position: Q1 2026 in Review

Barclays reduced its Zenas BioPharma (ZBIO) stake by 14% in Q1 2026, selling an estimated $107K and leaving 29,610 shares worth $579K. The position accounts for ﹤0.01% of the portfolio, ranked #3100.

Barclays first reported a position in ZBIO in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.25M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Barclays held 29,610 shares of Zenas BioPharma worth $579K as of Q1 2026.
  • Barclays sold 4,767 Zenas BioPharma shares in Q1 2026, an estimated $107K.
  • Zenas BioPharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3100 holding.
  • Barclays first reported a position in Zenas BioPharma in Q3 2024 and has held it in 7 quarters since.
  • Barclays's Zenas BioPharma position peaked at $1.25M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.